Last Updated : September 17, 2024
Details
Generic Name:
isatuximab
Project Status:
Pending
Therapeutic Area:
multiple myeloma not eligible for ASCT
Manufacturer:
Sanofi-Aventis Canada Inc. (Sanofi)
Call for patient/clinician input open:
Brand Name:
Sarclisa
Project Line:
Reimbursement Review
Project Number:
PC0378-000
Call for patient/clinician input closed:
Tumour Type:
Myeloma
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Sarclisa (isatuximab for injection) is indicated in combination with bortezomib, lenalidomide and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT) or with no intent for ASCT as initial therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Sarclisa (isatuximab for injection) is indicated in combination with bortezomib, lenalidomide and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT) or with no intent for ASCT as initial therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : September 17, 2024